Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Mar 14, 2015; 21(10): 3013-3019
Published online Mar 14, 2015. doi: 10.3748/wjg.v21.i10.3013
Table 2 Univariate analysis of negative prognostic factors of sustained virologic response in both dual and triple therapy
Dual therapy (P value)Triple therapy (P value)
Male sex0.330.39
Age ≥ 55 yr0.400.47
HCV genotype 1 and 40.46-
Liver stiffness > 12 kPa0.030.001
C/T or T/T IL28B genotype0.12-
> 500000 IU HCV RNA titre0.300.06